Press release
Chronic Hepatitis B Virus Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration by DelveInsight
Chronic Hepatitis B Virus Clinical Trials
Discover the latest drugs and treatment options in the Chronic Hepatitis B Virus Pipeline. Dive into DelveInsight's comprehensive report today! @ Chronic Hepatitis B Virus Pipeline Outlook - https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Chronic Hepatitis B Virus Pipeline Report
• In April 2025, Vir Biotechnology Inc. announced a phase 1b/2 platform study framework to evaluate the safety and efficacy of investigational candidate(s) and their combinations as potential treatments for adults with chronic hepatitis B virus infection.
• In April 2025, GlaxoSmithKline announced a study will assess the safety, efficacy and immune response following the sequential treatment of GlaxoSmithKline's (GSK) ASO compound (GSK3228836) and CHB-TI (GSK3528869A) in participants 18 to 65 years stable on NA treatment for CHB. The aim is to quantify the efficacy of sequential therapy as well as to determine an added value of sequential therapy over GSK3228836 therapy in CHB patients treated with NAs. In addition, the study will assess the effect of different treatment durations of GSK3228836 (12 or 24 weeks) prior to initiating GSK3528869A treatment.
• DelveInsight's Chronic Hepatitis B Virus pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Chronic Hepatitis B Virus treatment.
• The leading Chronic Hepatitis B Virus Companies such as Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm. And others.
• Promising Chronic Hepatitis B Virus Pipeline Therapies such as Peginterferon Alfacon, Daplusiran/Tomligisiran Dose Level 1, Bepirovirsen, Tenofovir disoproxil fumarate (TDF), VIR-2218, PEG-IFNα, and others.
Stay ahead with the most recent pipeline outlook for Chronic Hepatitis B Virus. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Chronic Hepatitis B Virus Treatment Drugs - https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Chronic Hepatitis B Virus Emerging Drugs Profile
Pradefovir: Ligand Pharmaceuticals
Pradefovir is an oral liver-targeting prodrug of the HBV DNA polymerase/reverse transcriptase inhibitor adefovir, for the potential treatment of hepatitis B virus (HBV) infection. The drug is developing using Ligand's HepDirect technology. Currently the product is in Phase III stage of development for the treatment of Chronic Hepatitis B.
RG6346: Dicerna Pharmaceuticals
RG6346 is an investigational GalXCTM RNAi therapeutic candidate in development in collaboration with Roche for the treatment of chronic HBV infection. RG6346 is designed to employ RNA interference to selectively knock down specific genes involved in the creation of HBV messenger RNA (mRNA) and the entry of the virus into liver cells. Preclinical data have demonstrated greater than 99.9% reduction in circulating HBsAg, as observed in mouse models of HBV infection. Unlike current therapies that typically provide long-term suppression of the virus, RG6346 has the potential to provide a functional cure for patients living with chronic HBV. Dicerna is currently conducting a Phase II trial of RG6346 in adult patients with chronic HBV infection.
The Chronic Hepatitis B Virus Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Hepatitis B Virus with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Hepatitis B Virus Treatment.
• Chronic Hepatitis B Virus Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Hepatitis B Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Hepatitis B Virus market
Explore groundbreaking therapies and clinical trials in the Chronic Hepatitis B Virus Pipeline. Access DelveInsight's detailed report now! @ New Chronic Hepatitis B Virus Drugs - https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Chronic Hepatitis B Virus Companies
Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm and others.
Chronic Hepatitis B Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Chronic Hepatitis B Virus Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Unveil the future of Chronic Hepatitis B Virus Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Chronic Hepatitis B Virus Market Drivers and Barriers - https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Chronic Hepatitis B Virus Pipeline Report
• Coverage- Global
• Chronic Hepatitis B Virus Companies- Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm. And others.
• Chronic Hepatitis B Virus Pipeline Therapies- Peginterferon Alfacon, Daplusiran/Tomligisiran Dose Level 1, Bepirovirsen, Tenofovir disoproxil fumarate (TDF), VIR-2218, PEG-IFNα, and others.
• Chronic Hepatitis B Virus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Hepatitis B Virus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Chronic Hepatitis B Virus Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Chronic Hepatitis B Virus Companies, Key Products and Unmet Needs - https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
• Introduction
• Executive Summary
• Chronic Hepatitis B Virus Infection: Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Chronic Hepatitis B Virus Infection - DelveInsight's Analytical Perspective
• Late Stage Products (Phase III)
• Pradefovir: Ligand Pharmaceuticals
• Drug profiles in the detailed report.....
• Mid Stage Products (Phase II)
• RG6346: Dicerna Pharmaceuticals
• Drug profiles in the detailed report.....
• Early Stage Products (Phase I/II)
• Drug name: Company name
• Drug profiles in the detailed report.....
• Early Stage Products (Phase I)
• VIR-3434: Vir Biotechnology
• Drug profiles in the detailed report.....
• Preclinical Stage Products
• SBT8230: Silverback Therapeutics
• Drug profiles in the detailed report.....
• Inactive Products
• Chronic Hepatitis B Virus Infection Key Companies
• Chronic Hepatitis B Virus Infection Key Products
• Chronic Hepatitis B Virus Infection - Unmet Needs
• Chronic Hepatitis B Virus Infection - Market Drivers and Barriers
• Chronic Hepatitis B Virus Infection - Future Perspectives and Conclusion
• Chronic Hepatitis B Virus Infection Analyst Views
• Chronic Hepatitis B Virus Infection Key Companies
• Appendix
Related Reports:
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/chronic-pain-market
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Adamantinoma Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Wound Irrigation Systems Market: https://www.delveinsight.com/report-store/wound-irrigation-systems-market?utm_source=Medgadget&utm_medium=pressrelease&utm_campaign=kupr
• Pulse Oximeter Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Diabetic Foot Ulcers Dfus Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Vertigo Market: https://www.delveinsight.com/report-store/vertigo-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Neuroprosthetics Market: https://www.delveinsight.com/blog/neuroprosthetics-market-analysis
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Dysthymia Market: https://www.delveinsight.com/report-store/persistent-depressive-disorder-market?utm_source=globenewswire&utm_medium=pressrelease&utm_campaign=spr
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Palmar Hyperhidrosis Market Size: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market
• X Linked Hypophosphatemia Market: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market
• Absssi Market Size: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-syndrome-market
• Central Pain Syndrome Market: https://www.delveinsight.com/report-store/central-pain-syndrome-market
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/blog/duchenne-muscular-dystrophy-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/ats-conference-coverage
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Hepatitis B Virus Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration by DelveInsight here
News-ID: 4083994 • Views: …
More Releases from DelveInsight Business Research
Global Intranasal Drug Delivery Market to reach USD 104,248.63 million by 2032 a …
According to DelveInsight's analysis, The Intranasal Drug Delivery market expansion is largely fueled by the growing burden of chronic conditions such as neurological, respiratory, severe allergic, and eye-related disorders. The rising preference for fast-acting, non-invasive drug delivery solutions is also boosting the market, as intranasal administration provides quick absorption and user-friendly dosing, improving both adherence and treatment outcomes. Additionally, increased research efforts and a wave of new product introductions from…
Global Clinical Trial Support Services Market to reach USD 43,160.56 million by …
According to DelveInsight's analysis, The clinical trial support services market is expanding swiftly, largely driven by the increasing incidence of chronic illnesses such as diabetes, cancer, and cardiovascular diseases. This rise has resulted in a higher volume of clinical trials, greater R&D spending, and stronger investment in new drug development. Moreover, the growing collaboration among pharmaceutical, biotechnology, and medical device companies is boosting the need for specialized services, including regulatory…
Global Respiratory Inhalers Market to reach USD 51,132.25 million by 2032 at a C …
According to DelveInsight's analysis, The demand for respiratory inhalers is rising sharply, driven by a combination of factors. Chief among these is the increasing prevalence of respiratory disorders, including asthma, COPD, bronchitis, and bronchospasm, which continue to impact a growing global population and create a need for fast and effective treatments. Simultaneously, patient awareness regarding early diagnosis and consistent management of asthma and COPD is improving, further supporting market growth.…
Global Dysmenorrhea Treatment Market to reach USD 7,909.14 million by 2032 at a …
According to DelveInsight's analysis, The widespread occurrence of dysmenorrhea (menstrual pain), along with rising awareness and better diagnostic practices, is driving strong growth in the dysmenorrhea treatment market. As more women seek professional care for menstrual pain, the need for effective therapies from OTC painkillers to hormonal treatments continues to increase. Awareness initiatives and educational programs are also reducing stigma and promoting earlier treatment-seeking behavior. Meanwhile, leading companies are advancing…
More Releases for Vir
Influenza A Market: Epidemiology, Therapies, Companies, DelveInsight | Cidara Th …
The influenza A market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM influenza A market size from 2020 to 2034. The report also covers current influenza A treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.
Influenza A therapies, such as XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others, are…
Influenza A Market: Epidemiology, Therapies, Companies, DelveInsight | Cidara Th …
Influenza A therapies, such as XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others, are expected to boost the Influenza A Market in the upcoming years.
DelveInsight has launched a new report on "Influenza A - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Influenza A, historical and forecasted epidemiology as well as the Influenza A market trends in the United States,…
Investigation for NASDAQ: VIR Investors over possible Wrongdoing at Vir Biotechn …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Vir Biotechnology, Inc.
Investors who purchased shares of Vir Biotechnology, Inc. (NASDAQ: VIR) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Vir Biotechnology directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Francisco, CA based…
SOFTWARE-DEFINED NETWORKING AND NETWORK FUTUALIZATION MARKET knowNCTION VIR indu …
“The SDN and NFV is picking up noticeable quality because of the developing mechanical progressions in systems administration and server farm union. SDN is a momentous systems administration design, which is ready to totally alter the current systems administration and server farm foundation. The SDN building structure is set to reclassify the systems administration framework to meet the developing number of system clients devouring a high data transfer capacity. With…
Investigation announced for Investors in shares of Vir Biotechnology, Inc. (NASD …
Vir Biotechnology, Inc is under investigation concerning potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Vir Biotechnology, Inc. (NASDAQ: VIR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Vir Biotechnology, Inc. regarding its business, its prospects and its operations were materially false…
Global Balancing Valves Market 2017 - IMI Hydronic, Danfoss, Frese A/S, Caleffi, …
"A balancing valve is a measurement and regulation device. Balancing valves are used in pressurized piping applications, such as HVAC and gas movement applications. The main purpose of a balancing valve is generally to create a consistent output pressure to a system from an inconsistent input pressure from a different system."
Scope of the Report:
This report focuses on the Balancing Valves in Global market, especially in North America, Europe and Asia-Pacific,…
